NCT04498936View on ClinicalTrials.gov

Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19

PHASE4CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

October 30, 2020

Study Completion Date

October 30, 2020

Conditions
COVID
Interventions
DRUG

Sofosbuvir and Ledipasvir

Evaluate the efficacy of Sofosbuvir/Ledipasvir in treatment of COVID-19

DRUG

Nitazoxanide

Evaluate the efficacy of Nitazoxanide in treatment of COVID-19

Trial Locations (2)

71515

Assiut University Hospital, Asyut

Unknown

15th May Hospital, Helwan

All Listed Sponsors
collaborator

Helwan University

OTHER

lead

Assiut University

OTHER

NCT04498936 - Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19 | Biotech Hunter | Biotech Hunter